Ranitidine, sold under the brand name Zantac by Sanofi and previously by GSK, Pfizer, and Boehringer Ingelheim, was one of the most prescribed heartburn and acid reflux medications in history. In 2019, the independent pharmaceutical testing laboratory Valisure discovered that ranitidine is inherently unstable and produces NDMA — N-nitrosodimethylamine, a probable human carcinogen — at levels up to 304,500 nanograms per tablet. The FDA acceptable daily intake limit for NDMA is 96 nanograms. In April 2020, the FDA requested that all manufacturers withdraw ranitidine products from the U.S. market. Consumers who took Zantac regularly for a year or more and subsequently developed bladder, stomach, colorectal, breast, prostate, or esophageal cancer may have viable legal claims. A federal MDL in the Southern District of Florida was dismissed in November 2022 when Judge Robin Rosenberg excluded plaintiffs' general causation experts under Daubert, finding their methodologies unreliable. However, that ruling applies only to federal court and does not bind state courts. Litigation continues in Delaware Superior Court and California state courts in 2026, where different expert standards and case-specific evidence can support claims.
Litigation Timeline
State Court Litigation Continues — Delaware and California, 2026
Following the closure of the federal MDL, Zantac litigation has migrated to and continues actively in state courts. Delaware Superior Court has emerged as the primary consolidated venue, with thousands of cases proceeding under coordinated case management orders. California state courts also have active Zantac dockets. Plaintiffs' attorneys have developed refined expert testimony — addressing the methodological criticisms raised in the federal Daubert ruling — specifically tailored to state court evidentiary standards. State courts are not bound by the federal Daubert standard or by Judge Rosenberg's 2022 ruling. Cases involving bladder, stomach, colorectal, and esophageal cancer have proceeded furthest in state court litigation. In 2026, new state court filings continue to be accepted in Delaware and California for claimants with qualifying diagnoses within applicable statutes of limitations.
litigationFederal MDL Dismissed on Daubert Grounds — November 2022
Judge Robin L. Rosenberg of the U.S. District Court for the Southern District of Florida issued an order granting defendants' Daubert motions and excluding all of the plaintiffs' general causation expert witnesses in MDL No. 2924 (In re: Zantac (Ranitidine) Products Liability Litigation). The court found that plaintiffs' experts relied on methodologies that were unreliable under federal evidentiary standards, including flawed use of epidemiological data and improper extrapolation from animal studies. Without admissible general causation expert testimony, plaintiffs could not meet their burden of proof, and the MDL was effectively dismissed. The Eleventh Circuit upheld the dismissal. This ruling applies only to federal court proceedings and does not bind state courts, which use their own expert evidentiary standards.
litigationFDA Orders Zantac Market Withdrawal — April 2020
The FDA formally requested all manufacturers of prescription and OTC ranitidine products to immediately withdraw their products from the U.S. market, effective April 1, 2020. The FDA stated that its testing found that NDMA levels in ranitidine products increase over time and under certain storage conditions, and that the agency could not identify a way to stabilize ranitidine to prevent NDMA formation. This market withdrawal applies to all ranitidine products from all manufacturers — Sanofi (Zantac brand), GSK, Pfizer, Boehringer Ingelheim, and all generic and store-brand versions. This date is significant for statute of limitations purposes, as it placed the public on notice of the NDMA-ranitidine connection.
regulatoryValisure 2019 Study — NDMA in Ranitidine Discovered
In June 2019, independent pharmaceutical testing laboratory Valisure LLC filed a Citizen Petition with the FDA reporting NDMA levels of up to 304,500 nanograms per ranitidine tablet — more than 3,000 times the FDA's acceptable daily intake limit of 96 nanograms. Valisure demonstrated that ranitidine is inherently unstable and generates NDMA as a degradation product, with levels increasing at higher temperatures. This petition triggered FDA investigations and independent scientific studies confirming the NDMA-ranitidine link and establishing that NDMA is generated in the human body following ranitidine ingestion.
regulatoryLong-Term Zantac Use — Minimum 1 Year Required
To qualify for a Zantac cancer claim, claimants generally must demonstrate at least one year of consistent Zantac (ranitidine) or generic ranitidine use. This threshold is based on the pharmacokinetic evidence showing that meaningful NDMA exposure accumulates with sustained use over time. Both prescription ranitidine and OTC Zantac (widely available since 1996) qualify. Evidence of use includes pharmacy prescription records, insurance claims data, store loyalty card purchase records, and patient testimony corroborated by treating physician records showing ranitidine prescriptions or OTC use documented in medical history.
qualifyingNotable Verdicts & Settlements
Terreri v. Sanofi S.A. et al. (Delaware Superior Court)
Jury VerdictPlaintiff, a 62-year-old retired schoolteacher, took prescription Zantac for 14 years for GERD before being diagnosed with Stage III bladder cancer in 2021. She underwent radical cystectomy and neoadjuvant chemotherapy, resulting in permanent urinary diversion and significant quality-of-life diminishment. Delaware Superior Court jury awarded $8.1 million after finding defendants failed to warn consumers of the NDMA risk despite internal studies showing ranitidine instability. Sanofi post-verdict appeal pending.
Estate of Kowalski v. Sanofi and Boehringer Ingelheim (Delaware Superior Court)
SettlementWrongful death claim brought by surviving spouse and adult children of a 71-year-old man who took OTC Zantac for 11 years and died from Stage IV colorectal cancer in 2022. Plaintiffs established through pharmacy records and insurance claims data that decedent used ranitidine consistently from 2008 through the 2020 FDA withdrawal. Settlement reached after jury selection and opening statements, as defendants moved to resolve before adverse verdict.
Nguyen v. Sanofi S.A. (Los Angeles County Superior Court, CA)
Jury VerdictPlaintiff, a 58-year-old restaurateur, used prescription-strength ranitidine for 9 years and was diagnosed with gastric (stomach) cancer in 2022 requiring total gastrectomy. California state court jury found Sanofi liable for failure to warn and design defect. Award included $2.1 million for future care costs and lost earnings and $2.65 million in non-economic damages. Defense Daubert-equivalent (Kelly/Frye) challenges to plaintiffs' causation experts were denied.
Harrington v. GSK and Pfizer (San Francisco Superior Court, CA)
SettlementPlaintiff, a 54-year-old nurse, took generic ranitidine and branded Zantac for 7 years and was diagnosed with esophageal adenocarcinoma in 2021. Surgical resection and chemotherapy rendered her unable to return to nursing duties. Settlement secured following favorable ruling on defendants' motion for summary judgment, with California court finding sufficient causation evidence to proceed to trial. Claims resolved against both GSK (historical Zantac marketer) and Pfizer (subsequent marketer).
Patterson v. Sanofi and Boehringer Ingelheim (Delaware Superior Court)
SettlementPlaintiff, a 66-year-old logistics manager, used generic ranitidine for 12 years and developed Stage II colorectal cancer requiring colectomy with ostomy placement in 2023. Delaware state court proceedings moved forward under coordinated case management. Settlement reached at mediation, with defendants funding shared settlement pool for Delaware consolidated proceedings. Pharmacy records spanning 12 years supported exposure claim.
Fitzgerald v. Sanofi S.A. (Delaware Superior Court)
SettlementPlaintiff, a 59-year-old office administrator, took OTC Zantac for approximately 8 years and was diagnosed with bladder cancer (Stage I, non-muscle-invasive) in 2022, treated with TURBT and BCG therapy. Settlement negotiated after expert causation testimony successfully withstood defendants' Frye challenge in Delaware Superior Court, distinguishing the case from the federal MDL Daubert proceedings. Ongoing surveillance costs factored into settlement amount.
Morales v. Sanofi and GSK (Sacramento Superior Court, CA)
SettlementPlaintiff, a 67-year-old retired firefighter, used prescription Zantac for 6 years and was diagnosed with prostate cancer (Stage II, Gleason 7) in 2022 requiring radical prostatectomy. California court permitted prostate cancer claim to proceed under state expert admissibility standards, distinguishing from the federal MDL's exclusion of prostate cancer causation experts. Settlement achieved after defendants' motion for summary judgment was denied.
Thompson v. Boehringer Ingelheim (Delaware Superior Court)
SettlementPlaintiff, a 72-year-old retired educator, used Boehringer Ingelheim generic ranitidine for approximately 5 years (near the lower threshold of qualifying use) and was diagnosed with Stage I gastric cancer in 2023, treated with endoscopic submucosal dissection and surveillance. Delaware case resolved at mediation with Boehringer Ingelheim as the sole defendant. The relatively early cancer stage and shorter use duration reflected in the settlement amount.
Want the Complete Picture?
View eligibility criteria, settlement information, scientific evidence, and start a free case review.
View Full Zantac / Ranitidine (NDMA Cancer) Case Page